Clinical curative effect of Febuxostat in the treatment of hyperuricemia in senile patients without gout

Abstract

Objective To observe the efficacy and safety of Febuxostat on elderly patients with hyperuricemia. Methods 112 elderly male patients with hyperuricemia, aged over 65 years with mean age of(72.6±5.8)years.All patients were randomly divided into Febuxostat 40 mg(37 cases), Febuxostat 80mg(38 cases)and Allopurinol(37 cases)groups.Blood samples were taken before and 2, 4, 8, 12, 16, 20, and 24 weeks after treatment.And fasting venous blood samples were taken for detections.The changes of blood uric acid level, blood biochemical indexes(triglyceride, low density lipoprotein cholesterol, urea, creatinine, Cystatin C, etc.)and side effects during treatment, and the blood uric acid targeting rate after 24 weeks of treatment were observed. Results After 2 weeks of treatment, the blood uric acid level was(500.23±54.72)μmol/L in Allopurinol group and(380.07±48.18)and(373.53±43.42)μmol/L in two Febuxostat groups, with the statistically significant difference(F=77.740, P=0.000). After 4 weeks, the level of serum uric acid was basically targeted in Febuxostat group, although Allopurinol group showed uric acid level was reduced, but was not less than the 356.88 μmol/L.After 4 weeks of treatment, serum uric acid level was(294.43±40.45)μmol/L in 80mg febuxostat group, (312.86±38.66)μmol/L in Febuxostat 40 mg group, (464.54±51.75)μmol/L in allopurinol group(F=165.330, P=0.000). After 8 weeks of treatment, the blood uric acid level was basically targeted in all three groups.Compared with pre-treatment, after the treatment, the serum levels of low density lipoprotein cholesterol, Cystatin C and creatinine in the groups of 40 mg and 80 mg Febuxostat showed a certain degree of reduction(P=0.027, 0.039; both P=0.004, P=0.037, 0.000 respectively). And no serious adverse reactions were found. Conclusions Compared with Allopurinol treatment, Febuxostat tretment shows that the blood uric acid level drops faster, the target-reaching rate is higher at the end of treatment, no serious side effects are observed, and it may improve blood lipid regulation and renal protection. Key words: Hyperuricemia; Xanthine oxidase